Mercer Global Advisors’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$866K Buy
+51,203
New +$766K ﹤0.01% 1939
2025
Q3
– Sell
-36,452
Closed -$776K – 2734
2025
Q2
$776K Sell
36,452
-943
-3% -$21.5K ﹤0.01% 1336
2025
Q1
$721K Sell
37,395
-7,283
-16% -$146K ﹤0.01% 1291
2024
Q4
$797K Sell
44,678
-131
-0.3% -$2.54K ﹤0.01% 1211
2024
Q3
$901K Sell
44,809
-2,442
-5% -$34.2K ﹤0.01% 1058
2024
Q2
$369K Sell
47,251
-1,951
-4% -$10.5K ﹤0.01% 1475
2024
Q1
$204K Buy
49,202
+902
+2% +$3.59K ﹤0.01% 1776
2023
Q4
$126K Hold
48,300
– – ﹤0.01% 1892
2023
Q3
$90K Hold
48,300
– – ﹤0.01% 1861
2023
Q2
$121K Buy
48,300
+5,200
+12% +$9.49K ﹤0.01% 1809
2023
Q1
$75K Hold
43,100
– – ﹤0.01% 1845
2022
Q4
$183K Buy
43,100
+800
+2% +$1.46K ﹤0.01% 1729
2022
Q3
$50K Buy
42,300
+2,100
+5% +$2.38K ﹤0.01% 1769
2022
Q2
$40K Buy
40,200
+15,300
+61% +$21.4K ﹤0.01% 1777
2022
Q1
$61K Buy
24,900
+2,950
+13% +$7.44K ﹤0.01% 1829
2021
Q4
$59K Buy
21,950
+4,000
+22% +$19.2K ﹤0.01% 1746
2021
Q3
$90K Hold
17,950
– – ﹤0.01% 1693
2021
Q2
$134K Buy
17,950
+1,000
+6% +$6.56K ﹤0.01% 1604
2021
Q1
$99K Buy
+16,950
New +$109K ﹤0.01% 1553

Other funds holding SMMT

Mercer Global Advisors's SMMT Position: Q3 2026 in Review

Mercer Global Advisors opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 51,203 shares worth $866K. The stake represents ﹤0.01% of the portfolio and ranks #1939 among its holdings. This is a return to the name: Mercer Global Advisors previously reported a position in SMMT as recently as Q2 2025.

Mercer Global Advisors first reported a position in SMMT in Q1 2021 and has held it in 19 quarters since. The position peaked at $901K in Q3 2024. 298 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Mercer Global Advisors held 51,203 shares of Summit Therapeutics worth $866K as of Q3 2026.
  • Summit Therapeutics was a new Mercer Global Advisors position in Q3 2026.
  • Summit Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q3 2026, its #1939 holding.
  • Mercer Global Advisors first reported a position in Summit Therapeutics in Q1 2021 and has held it in 19 quarters since.
  • Mercer Global Advisors's Summit Therapeutics position peaked at $901K in Q3 2024.
  • 298 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Mercer Global Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.